Tuberculosis Treatment With a 3-Drug Rifamycin-Free Regimen in Liver Transplant Recipients

Liver Transpl. 2020 Jan;26(1):160-163. doi: 10.1002/lt.25654. Epub 2019 Nov 25.

Authors

Timothy Sullivan¹, Samantha Jacobs¹, Jennifer Leong², Dallas Dunn¹, Emily Baneman¹, Sarah Taimur¹, Shirish Huprikar¹, Meenakshi Rana¹

Affiliations

¹ Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY.
² The Recanati/Miller Transplantation Institute and Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY.

PMID: 31606934
DOI: 10.1002/lt.25654

No abstract available

Publication types

Letter

MeSH terms

Antitubercular Agents / adverse effects
Humans
Liver Transplantation* / adverse effects
Pharmaceutical Preparations*
Transplant Recipients
Tuberculosis* / drug therapy

Substances

Antitubercular Agents
Pharmaceutical Preparations